$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000114420417057793 Filed on November 09, 2017

Income Statement

Concept	2017 Q3	2016 Q3
Revenue	$1.624M	$2.686M
YoY Change	-39.55%	-8.86%
Cost Of Revenue	$614.9K	$1.851M
YoY Change	-66.78%	30.81%
Gross Profit	$1.009M	$835.0K
YoY Change	20.8%	-45.5%
Gross Profit Margin	62.12%	31.09%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$2.287M	$1.267M
YoY Change	80.51%	-69.64%
% of Gross Profit	226.69%	151.7%
Depreciation & Amortization	$226.0K	$165.8K
YoY Change	36.32%	3.12%
% of Gross Profit	22.41%	19.86%
Operating Expenses	$3.139M	$2.040M
YoY Change	53.85%	-61.5%
Operating Profit	-$2.130M	-$1.205M
YoY Change	76.75%	-68.01%
Interest Expense	$82.54K	$57.38K
YoY Change	43.86%	-10.1%
% of Operating Profit
Other Income/Expense, Net	$3.945M	$5.443M
YoY Change	-27.52%	160.93%
Pretax Income	$1.815M	$4.238M
YoY Change	-57.17%	-352.06%
Income Tax	$0.00	$0.00
% Of Pretax Income	0.0%	0.0%
Net Earnings	$1.815M	$4.238M
YoY Change	-57.17%	-352.11%
Net Earnings / Revenue	111.79%	157.78%
Basic Earnings Per Share	$0.00	$0.03
Diluted Earnings Per Share	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	782.4M shares	806.9M shares
Diluted Shares Outstanding	788.8M shares	816.0M shares

Balance Sheet

Concept	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.560M	$12.58M
YoY Change	-39.9%	39.31%
Cash & Equivalents	$7.947M	$12.58M
Short-Term Investments
Other Short-Term Assets	$260.0K	$300.0K
YoY Change	-13.33%	0.0%
Inventory	$5.710M	$5.640M
Prepaid Expenses
Receivables	$1.090M	$1.150M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$14.61M	$19.66M
YoY Change	-25.69%	39.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.270M	$8.352M
YoY Change	10.99%	10.55%
Goodwill
YoY Change
Intangibles		$6.418M
YoY Change		0.28%
Long-Term Investments	$50.00K	$50.00K
YoY Change	0.0%	0.0%
Other Assets	$390.0K	$390.0K
YoY Change	0.0%	-39.92%
Total Long-Term Assets	$17.40M	$15.21M
YoY Change	14.4%	676.02%
TOTAL ASSETS
Total Short-Term Assets	$14.61M	$19.66M
Total Long-Term Assets	$17.40M	$15.21M
Total Assets	$32.01M	$34.87M
YoY Change	-8.2%	21.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$860.0K	$2.280M
YoY Change	-62.28%	-36.85%
Accrued Expenses	$1.340M	$1.430M
YoY Change	-6.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due	$440.0K	$410.0K
YoY Change	7.32%	-12.77%
Total Short-Term Liabilities	$3.650M	$5.135M
YoY Change	-28.92%	13.91%
LONG-TERM LIABILITIES
Long-Term Debt	$3.320M	$1.980M
YoY Change	67.68%	-4.12%
Other Long-Term Liabilities	$4.950M	$35.25K
YoY Change	13942.15%	-93.58%
Total Long-Term Liabilities	$8.270M	$7.260M
YoY Change	13.92%	-37.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.650M	$5.135M
Total Long-Term Liabilities	$8.270M	$7.260M
Total Liabilities	$11.92M	$12.39M
YoY Change	-3.83%	-23.52%
SHAREHOLDERS EQUITY
Retained Earnings		-$137.3M
YoY Change		0.28%
Common Stock		$160.1M
YoY Change		36.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$306.8K
YoY Change		0.0%
Treasury Stock Shares	100.0K shares	100.0K shares
Shareholders Equity	$20.09M	$22.48M
YoY Change
Total Liabilities & Shareholders Equity	$32.01M	$34.87M
YoY Change	-8.2%	21.5%

Cashflow Statement

Concept	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	$1.815M	$4.238M
YoY Change	-57.17%	-352.11%
Depreciation, Depletion And Amortization	$226.0K	$165.8K
YoY Change	36.32%	3.12%
Cash From Operating Activities	-$2.230M	-$2.320M
YoY Change	-3.88%	-33.33%
INVESTING ACTIVITIES
Capital Expenditures	-$120.0K	-$240.0K
YoY Change	-50.0%	-65.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$120.0K	-$240.0K
YoY Change	-50.0%	-65.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	330.0K	2.320M
YoY Change	-85.78%	45.0%
NET CHANGE
Cash From Operating Activities	-2.230M	-2.320M
Cash From Investing Activities	-120.0K	-240.0K
Cash From Financing Activities	330.0K	2.320M
Net Change In Cash	-2.020M	-240.0K
YoY Change	741.67%	-90.7%
FREE CASH FLOW
Cash From Operating Activities	-$2.230M	-$2.320M
Capital Expenditures	-$120.0K	-$240.0K
Free Cash Flow	-$2.110M	-$2.080M
YoY Change	1.44%	-25.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	925	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Notes Issued1 NotesIssued1	1200000	USD
	us-gaap	Notes Issued1 NotesIssued1	0	USD
	eltp	Retirement Of Common Shares Pursuant To Issuance Of Series J Convertible Preferred Shares RetirementOfCommonSharesPursuantToIssuanceOfSeriesJConvertiblePreferredShares	20378631	USD
	eltp	Retirement Of Common Shares Pursuant To Issuance Of Series J Convertible Preferred Shares RetirementOfCommonSharesPursuantToIssuanceOfSeriesJConvertiblePreferredShares	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	955691	USD
CY2016Q3	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	2033074	USD
CY2017Q3	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	1066227	USD
CY2016Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	652624	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	1815183	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	4238098	USD
CY2017Q3	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	0	USD
CY2016Q3	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	22857143	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1815183	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4238098	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	4419	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3147	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1815183	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	27095241	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	412719	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	345419	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4162436	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7896849	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	923500	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	1232950	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	170758	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	187920	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	151219	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-384793	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-707134	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2341806	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-208223	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-75889	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	116962	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-506667	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-506664	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3317495	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3081435	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-462763	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-519392	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	386564	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	513359	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	75274	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6033	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	181908	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1277678	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	742210	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4668331	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3038048	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1067504	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11512179	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12579683	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-571135	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	939318	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	60085	USD
	eltp	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	5205	USD
	eltp	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	-12171	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	260432	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	185143	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	49957	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	17669	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	251504	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	66006	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-718309	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4531774	USD
	us-gaap	Interest Paid InterestPaid	38215	USD
	us-gaap	Interest Paid InterestPaid	120508	USD
	us-gaap	Net Income Loss NetIncomeLoss	-353577	USD
	us-gaap	Net Income Loss NetIncomeLoss	5332122	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	390006	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	389081	USD
CY2016Q3	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	28354070	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2207993	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1258829	USD
CY2016Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9158246	shares
CY2017Q3	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	4023176	USD
CY2017Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6369237	shares
CY2017Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	5221600	USD
CY2017Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5911223	USD
CY2017Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	229879	USD
CY2017Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	283086	USD
CY2017Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	257353	USD
CY2017Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	221657	USD
CY2017Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	USD
CY2017Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7837382	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7426752	USD
CY2017Q3	us-gaap	Depreciation Depreciation	410630	USD
CY2016Q3	us-gaap	Depreciation Depreciation	165815	USD
CY2017Q3	eltp	Bond Issue Costs BondIssueCosts	354453	USD
CY2017Q1	eltp	Bond Issue Costs BondIssueCosts	354453	USD
CY2017Q3	eltp	Accumulated Amortization Of Bond AccumulatedAmortizationOfBond	171320	USD
CY2017Q1	eltp	Accumulated Amortization Of Bond AccumulatedAmortizationOfBond	164231	USD
CY2017Q3	eltp	Unamortization Of Bond UnamortizationOfBond	183133	USD
CY2017Q1	eltp	Unamortization Of Bond UnamortizationOfBond	190222	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	40781	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	43329	USD
CY2017Q3	us-gaap	Deferred Revenue DeferredRevenue	2772223	USD
CY2017Q1	us-gaap	Deferred Revenue DeferredRevenue	3278890	USD
CY2016Q1	eltp	Warrants Outstanding WarrantsOutstanding	41586066	shares
CY2017Q1	eltp	Warrants Outstanding WarrantsOutstanding	9379219	shares
CY2017Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.0625
CY2017Q3	eltp	Warrants Outstanding WarrantsOutstanding	85477348	shares
CY2016Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.0625
CY2017	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	32206847	shares
	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	2910532	shares
	eltp	Warrants Granted During Period WarrantsGrantedDuringPeriod	79008661	shares
CY2017	eltp	Warrants Granted During Period WarrantsGrantedDuringPeriod	0	shares
	eltp	Warrants Granted During Period Weighted Average Exercise Price WarrantsGrantedDuringPeriodWeightedAverageExercisePrice	0.1521
CY2017	eltp	Warrants Granted During Period Weighted Average Exercise Price WarrantsGrantedDuringPeriodWeightedAverageExercisePrice	0
CY2017Q2	eltp	Warrant Expiration Period WarrantExpirationPeriod	P10Y
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P9Y6M29D
CY2017Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P10Y
	eltp	Derivative Liabilities Warrant Issued During Period DerivativeLiabilitiesWarrantIssuedDuringPeriod	6474674	USD
	eltp	Derivative Liability Warrants Change In Fair Value Of Warrant Liability DerivativeLiabilityWarrantsChangeInFairValueOfWarrantLiability	4162436	USD
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	621750	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6737667	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	560000	shares
CY2017Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2017Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	50	shares
CY2017Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2017Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	24.0344	shares
CY2017Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2017Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	24.0344	shares
CY2017Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	786046966	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	785946966	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7081000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.20
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.16
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	216667	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5041000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.20
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.17
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.15
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	258747	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	93740	USD
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	93290	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2017Q3	eltp	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.10
CY2017Q1	eltp	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.15
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	eltp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	79215	USD
CY2017	eltp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	373055	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	170758	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	357955	USD
CY2017Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2017Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	928031448	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	927931448	shares
CY2017Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2017Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	2077123	USD
	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	4584932	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1249228	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1371912	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	3326351	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	5956844	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1630001	USD
	us-gaap	Cost Of Revenue CostOfRevenue	4029246	USD
	us-gaap	Gross Profit GrossProfit	1696350	USD
	us-gaap	Gross Profit GrossProfit	1927598	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4429747	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2786154	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1453034	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	989274	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	170758	USD
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	20378631	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	23571429	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1368562	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	174169	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13953	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	43376	USD
	us-gaap	Operating Expenses OperatingExpenses	6067492	USD
	us-gaap	Operating Expenses OperatingExpenses	4372261	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4371142	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2444663	USD
	us-gaap	Interest Expense InterestExpense	153272	USD
	us-gaap	Interest Expense InterestExpense	126320	USD
	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	4162436	USD
	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	7896849	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	8401	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6256	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4017565	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7776785	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-353577	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5332122	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-353577	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	26046408	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	800772162	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	765055707	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	807141399	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	774213953	shares
	eltp	Stock Issued During Period Value Execution Of Warrants StockIssuedDuringPeriodValueExecutionOfWarrants	181908	USD
	eltp	Stock Issued During Period Value Initial Issues StockIssuedDuringPeriodValueInitialIssues	919732	USD
	eltp	Stock Issued During Period Value Additional Issues StockIssuedDuringPeriodValueAdditionalIssues	19586	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	955691	USD
	us-gaap	Revenue Recognition Milestone Method Milestone RevenueRecognitionMilestoneMethodMilestone	The milestones, totaling $500k (with $405k already received), consist of amounts due upon the first shipment of each identified product, as follows: Phentermine 37.5mg tablets ($145k), Phentermine 15 &amp; 30mg capsules ($45k), Hydromorphone 8mg ($125k), Naltrexone 50mg ($95k) and the balance of $95k due in relation to the first shipment of generic products which still require marketing authorizations from the FDA, and to which there can be no assurances of such marketing authorizations being granted and accordingly there can be no assurances that the Company will earn and receive these milestone amounts.
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	4162436	USD
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	28611135	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4516013	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2564727	USD
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6369237	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9158246	shares
CY2017Q3	us-gaap	Inventory Gross InventoryGross	5708832	USD
CY2017Q1	us-gaap	Inventory Gross InventoryGross	6415966	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17104223	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16466156	USD
	us-gaap	Depreciation Depreciation	226044	USD
	us-gaap	Depreciation Depreciation	338330	USD
CY2017Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	6419091	USD
	eltp	Intangible Assets Excluding Goodwill Acquired IntangibleAssetsExcludingGoodwillAcquired	1275274	USD
CY2017Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	6411799	USD
CY2017	eltp	Intangible Assets Excluding Goodwill Acquired IntangibleAssetsExcludingGoodwillAcquired	7292	USD
CY2017Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	19022	USD
CY2016Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	21042	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">NOTE 10. COMMITMENTS AND CONTINGENCIES</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s condensed consolidated financial statements. Contingencies are inherently unpredictable and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Operating Leases 135 Ludlow Ave.</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company entered into an operating lease for a portion of a one-story warehouse, located at 135 Ludlow Avenue, Northvale, New Jersey (the “135 Ludlow Ave. lease”). The <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 135</font> Ludlow Ave. lease is for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000</font></font> square feet of floor space and began on July 1, 2010. During July 2014, the Company modified the 135 Ludlow Ave. lease in which the Company was permitted to occupy the entire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35,000</font> square feet of floor space in the building (“135 Ludlow Ave. modified lease”).</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The 135 Ludlow Ave. modified lease, includes an initial term, which expired on December 31, 2016 with two tenant renewal options of five years each, at the sole discretion of the Company. On June 22, 2016, the Company exercised the first of these renewal options, with such option including a term that begins on January 1, 2017 and expires on December 31, 2021.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The 135 Ludlow Ave. property required significant leasehold improvements and qualifications, as a prerequisite, for its intended future use. Manufacturing, packaging, warehousing and regulatory activities are currently conducted at this location. Additional renovations and construction to further expand the Company’s manufacturing resources are in progress.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Rent expense is recorded on the straight-line basis. Rents paid in excess is recognized as deferred rent. Rent expense under the 135 Ludlow Ave. modified lease for the three-month ended September 30, 2017 and 2016 was $54,909 and $45,213, respectively and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">109,818</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,426</font> for the six months ended September 30, 2017 and 2016, respectively. Rent expense is recorded in general and administrative expense in the unaudited condensed consolidated statements of operations. Deferred rent as of September 30, 2017 and March 31, 2017 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,453</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,152</font>, respectively and recorded as a component of other long-term liabilities.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company has an obligation for the restoration of its leased facility and the removal or dismantlement of certain property and equipment as a result of its business operation in accordance with ASC 410, <i> Asset Retirement and Environmental Obligations Asset Retirement Obligations</i>. The Company records the fair value of the asset retirement obligation in the period in which it is incurred. The Company increases, annually, the liability related to this obligation. The liability is accreted to its present value each period and the capitalized cost is depreciated over the useful life of the related asset. Upon settlement of the liability, the Company records either a gain or loss. As of September 30, 2017, and March 31, 2017, the Company had a liability of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,516</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">29,616</font>, respectively and recorded as a component of other long-term liabilities.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q3	eltp	Closing Price On Valuation Date ClosingPriceOnValuationDate	0.10
CY2017Q1	eltp	Closing Price On Valuation Date ClosingPriceOnValuationDate	0.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.214	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.232	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.2	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.21	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.022	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.024	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.015	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.025	pure
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	85000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	220000	USD

Files In Submission

Name	View Source	Status
0001144204-17-057793-index-headers.html	Edgar Link	pending
0001144204-17-057793-index.html	Edgar Link	pending
0001144204-17-057793.txt	Edgar Link	pending
0001144204-17-057793-xbrl.zip	Edgar Link	pending
eltp-20170930.xml	Edgar Link	completed
eltp-20170930.xsd	Edgar Link	pending
eltp-20170930_cal.xml	Edgar Link	unprocessable
eltp-20170930_def.xml	Edgar Link	unprocessable
eltp-20170930_lab.xml	Edgar Link	unprocessable
eltp-20170930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv477933_10q.htm	Edgar Link	pending
tv477933_ex31-1.htm	Edgar Link	pending
tv477933_ex31-2.htm	Edgar Link	pending
tv477933_ex32-1.htm	Edgar Link	pending
tv477933_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2017 Q3 Form 10-Q Financial Statement

#000114420417057793 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2017 Q3 Form 10-Q Financial Statement

#000114420417057793 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp